Breaking News Instant updates and real-time market news.

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

, LZB

La-Z-Boy

$31.25

0.1 (0.32%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40

On The Fly: After Hours Movers

HIGHER: Maxim Integrated (MXIM), up 0.25% after it said in a regulatory filing that, last week, it named Sumeet Gagneja to serve as its principal accounting officer. DOWN AFTER EARNINGS: La-Z-Boy (LZB), down 13.8%... Cree (CREE), down 8%... 21Vianet (VNET), down 6.1%... Salesforce.com (CRM), down 1%. ALSO LOWER: root9B Holdings (RTNB), down 47.7% after it said it secured incremental funding of $500,000 to allow the company to meet its payroll obligations and said that there is no change in the foreclosure proceedings... Ultragenyx (RARE), down 10.1% after it said it plans to discontinue further clinical development of Ace-ER.

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

LZB

La-Z-Boy

$31.25

0.1 (0.32%)

CREE

Cree

$23.03

0.46 (2.04%)

VNET

21Vianet

$4.58

0.03 (0.66%)

CRM

Salesforce

$92.95

1.19 (1.30%)

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

RARE

Ultragenyx

$58.85

1.94 (3.41%)

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

  • 16

    Nov

MXIM Maxim Integrated
$44.39

0.68 (1.56%)

07/21/17
DBAB
07/21/17
NO CHANGE
Target $50
DBAB
Buy
Maxim Integrated weakness a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Ross Seymore views near-term weakness in shares of Maxim Integrated following the company's Q4 results as a buying opportunity. Weaker than expected sales in Q4 and guidance "will overwhelm" any positive takes on the company's "impressive" margins, Seymore tells investors in a research note. The analyst likes the stock's risk/reward and keeps a Buy rating on the name with a $50 price target.
06/15/17
RAJA
06/15/17
INITIATION
RAJA
Market Perform
Maxim Integrated resumed with a Market Perform at Raymond James
Raymond James analyst Chris Caso resumed coverage on Maxim with a Market Perform citing valuation.
04/21/17
EVER
04/21/17
DOWNGRADE
Target $46
EVER
In Line
Maxim Integrated downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst C.J. Muse downgraded Maxim Integrated saying the diversification/margin story is largely complete and shares are near his $46 price target. Muse sees modest headwinds ahead including slowing China BMS business and lack of Apple exposure in 2H and recommends moving to the sidelines.
04/21/17
LOOP
04/21/17
NO CHANGE
Target $51
LOOP
Buy
Maxim auto worries 'much ado about nothing,' says Loop Capital
Loop Capital analyst Betsy Van Hees attributes the after-hours weakness in Maxim Integrated shares despite the company's strong Q3 report and Q4 guidance to concerns over auto market commentary that may have been misinterpreted. After following up with management, she confirmed they were not making a broad sector call and she views concerns over a flat sequential guide in automotive as "much ado about nothing." Van Hees reiterates her Buy rating and $51 price target on Maxim shares.
LZB La-Z-Boy
$31.25

0.1 (0.32%)

02/23/17
02/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. NVIDIA (NVDA) downgraded to Underperform from Market Perform at BMO Capital and to Reduce from Buy at Nomura. 2. L Brands (LB) downgraded to Neutral from Overweight at Atlantic Equities. 3. FLIR Systems (FLIR) downgraded to In-Line from Outperform at Imperial Capital with analyst Jeff Kessler citing valuation following the recent rally in the shares. The analyst maintains a $38 price target for the stock. 4. La-Z-Boy (LZB) downgraded to Hold from Buy at Stifel with analyst John Baugh saying the company's January quarter results show that it is having difficulty generating organic growth. The analyst adds that "the furniture business remains challenged." 5. Dorman Products (DORM) downgraded to Market Perform from Outperform at FBR Capital with analyst Christopher Van Horn citing valuation. The analyst raised his price target for the shares to $80 from $68. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/23/17
STFL
02/23/17
DOWNGRADE
STFL
Hold
La-Z-Boy downgraded on results, sectior weakness at Stifel
Stifel analyst John Baugh downgraded La-Z-Boy, as he says that the company's January quarter results show that it is having difficulty generating organic growth. The analyst adds that "the furniture business remains challenged." Target to $30 from $33.
08/01/17
SIDC
08/01/17
DOWNGRADE
SIDC
Neutral
La-Z-Boy downgraded to Neutral from Buy at Sidoti
Sidoti analyst Anthony Lebiedzinski downgraded La-Z-Boy to Neutral due to shares approaching his $36 price target.
08/01/17
08/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MGM Resorts (MGM) downgraded to Neutral from Buy at UBS with analyst Robin Farley saying the current valuation, with the shares up 37% over the past 12 months, now captures much of the value of the REIT transaction and improving Las Vegas outlook. 2. Boardwalk Pipeline (BWP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying she expects the stock to be "range bound" until its 2019-2020 outlook become clearer. 3. La-Z-Boy (LZB) downgraded to Neutral from Buy at Sidoti with analyst Anthony Lebiedzinski saying shares are approaching his $36 price target. 4. Regeneron (REGN) downgraded to Underperform from Neutral at Baird with analyst Brian Skorney saying Dupixent expectations have gotten ahead of themselves and consensus numbers currently reflect an overlap with Cosentyx sales which looks like an overestimate. 5. Corporate Office Properties (OFC) downgraded to Sell from Hold at Stifel with analyst John Guinee saying he believes that the Real Estate Investment Trust will be hurt by "persistently weak leasing economics," the expirations of a large number of its leases with high rents, and efforts by defense and IT organization to keep rent costs low. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CREE Cree
$23.03

0.46 (2.04%)

04/27/17
ROTH
04/27/17
NO CHANGE
Target $27
ROTH
Buy
Cree price target lowered to $27 from $33 at Roth Capital
Roth Capital analyst Craig Irwin lowered his price target for Cree to $27 from $33 on valuation. Nonetheless, the analyst believes that with a smaller miss than peers coming from the weak January and transitory driver issues, weakness is overdone. That being said, the turnaround in Lighting Products is taking longer than anyone would like, he adds. Irwin reiterates a Buy rating on the shares.
05/22/17
05/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan with analyst Rod Hall saying while more negative news from the Apple (AAPL) royalty suit is likely, "material fundamental upside" exists from the closure of the NXP Semiconductors (NXPI) by the end of this year. The analyst views the deal as highly accretive. Hall also believes Apple ultimately will want to preserve its commercial relationship with Qualcomm. 2. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at Raymond James with analyst Tavis McCourt saying shares look increasingly attractive based on improved demand visibility that is less economically sensitive than many of its peers, and demand catalysts from FirstNet buildouts that are expected to start in 2018. 3. Entegris (ENTG) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Toshiya Hari citing the recent pullback in shares and maintained a $29 price target. 4. Blackstone (BX) upgraded to Buy from Neutral at Citi with analyst William Katz saying the company's intentions to raise a $40B infrastructure fund should be a "valuation catalyst." 5. Cree (CREE) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he thinks that the company's new CEO could make positive changes at the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/17
ROTH
06/20/17
NO CHANGE
Target $29
ROTH
Buy
Wolfspeed's potential future value to Cree underappreciated, says Roth Capital
Roth Capital analyst Craig Irwin estimates that the Wolfspeed segment could drive $2.4B-$3.1B in value for Cree over the next eight years, which implies a current value of $12-$17 per share, though he argues that is currently being underappreciated by the market. Irwin, who keeps a Buy rating on Cree, raised his price target on the shares to $29 from $27.
05/22/17
JMPS
05/22/17
UPGRADE
JMPS
Outperform
Cree upgraded to Outperform from Market Perform at JMP Securities
JMP Securities analyst Joseph Osha upgraded Cree as he indicates that he thinks that the company's new CEO could make positive changes at the company. Target $29.
VNET 21Vianet
$4.58

0.03 (0.66%)

05/22/17
MSCO
05/22/17
NO CHANGE
MSCO
21Vianet named a long Research Tactical Idea at Morgan Stanley (pre-open)
CRM Salesforce
$92.95

1.19 (1.30%)

08/18/17
RBCM
08/18/17
NO CHANGE
RBCM
Salesforce billings growth can beat expectations, says RBC Capital
RBC Capital analyst Ross MacMillan believes that Salesforce's Q2 billings growth will beat expectations, and he preidtcs that it will raise its full-year revenue growth guidance. The analyst is upbeat on the company's fundamentals and keeps an Outperform rating.
08/21/17
RHCO
08/21/17
NO CHANGE
RHCO
Salesforce Q2 results likely to beat expectations, says SunTrust
SunTrust analyst Terry Tillman expects Salesforce's Q2 results to beat expectations "based on well-balanced growth across (its) Sales, Service, Marketing and Platform businesses." Tillman thinks that the company will perform well in 2H18 due to seasonal billings strength, a number of "Event driven catalysts" including its Dreamforce conference, and the increased monetization of its "newer cloud products." He expects the company's fiscal 2019 results to significantly beat expectations and expects the stock to perform well in the second half of this year. He keeps a $110 price target and a Buy rating on the shares.
08/22/17
BTIG
08/22/17
NO CHANGE
BTIG
Salesforce Q2 results likely to beat expectations, says BTIG
BTIG analyst Joel Fishbein, Jr says his checks with Salesforce's partners have convinced him that the company's Q2 results will beat expectations. The analyst says checks indicate that the company has a strong pipeline and stable pricing, and is benefiting from more "multi-cloud deployments and deeper penetration of the installed base." The analyst says the all of the company's "segments continue to show strength," while its ARPU continues to rise. He keeps a $100 price target and a Buy rating on the shares.
08/22/17
ROTH
08/22/17
NO CHANGE
Target $112
ROTH
Buy
Salesforce price target raised to $112 from $103 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Salesforce to $112 from $103 saying earnings comparisons are set to improve materially in Q2 and 2H18. The analyst reiterates a Buy rating on the shares.
RTNB root9B Technologies
$2.98

1.72 (136.51%)

RARE Ultragenyx
$58.85

1.94 (3.41%)

05/05/17
LEER
05/05/17
NO CHANGE
Target $89
LEER
Outperform
Ultragenyx price target lowered to $89 from $93 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Ultragenyx to $89 from $93 as he delays launch assumptions for triheptanoin programs to 2020 from 2019. Nonetheless, the analyst notes that the company announced pre-specified fracture healing data in X-linked hypophosphatemia patients who were enrolled in the recent Phase 3 study, which suggest burosumab is disease-modifying and correlates biomarker improvements to physiological benefit. He continues to assign 90% probability of success to burosumab, and reiterates an Outperform rating on the shares.
07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
Ultragenyx initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of Ultragenyx with a $72 price target and a Market Perform rating. The analyst views the stock as fully valued.
07/27/17
07/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kinder Morgan (KMI) initiated with a Neutral at Mizuho. 2. Alpine Immune Sciences (ALPN) initiated with a Buy at Ladenburg. 3. Synaptics (SYNA) resumed with an Outperform at Cowen. 4. BioMarin (BMRN) and Ultragenyx (RARE) were initiated with a Market Perform at Bernstein. 5. Keane Group (FRAC) and ProPetro Holding (PUMP) were initiated with an Overweight at Capital One. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
EVER
08/16/17
INITIATION
Target $63
EVER
In Line
Ultragenyx initiated with an In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Ultragenyx with an In Line and a $63 price target.

TODAY'S FREE FLY STORIES

CELC

Celcuity

20:34
09/19/17
09/19
20:34
09/19/17
20:34
Syndicate
Celcuity 2.4M share IPO priced at $9.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

BSTI

BEST Inc

20:33
09/19/17
09/19
20:33
09/19/17
20:33
Syndicate
Best Inc 45M share IPO priced at $10.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

20:25
09/19/17
09/19
20:25
09/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

PCRX

Pacira

$35.70

-0.6 (-1.65%)

20:00
09/19/17
09/19
20:00
09/19/17
20:00
Recommendations
Pacira analyst commentary  »

Pacira's Exparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AVEVF

Aveva

19:56
09/19/17
09/19
19:56
09/19/17
19:56
Upgrade
Aveva rating change at Goldman Sachs »

Aveva upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

18:58
09/19/17
09/19
18:58
09/19/17
18:58
Syndicate
Zai Lab announces upsizing of U.S. IPO of American depositary shares »

Zai Lab announces its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Hot Stocks
Omega Healthcare provides hurricane update »

Omega Healthcare provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

F

Ford

$11.72

0.09 (0.77%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Periodicals
Ford to slash production at five North American assembly plants, Reuters says »

Ford announced it intends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 26

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

18:26
09/19/17
09/19
18:26
09/19/17
18:26
Hot Stocks
FedEx says without cyberattack FY18 guidance would not have changed »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

EE

El Paso Electric

$54.85

0.05 (0.09%)

18:25
09/19/17
09/19
18:25
09/19/17
18:25
Hot Stocks
El Paso Electric announces City of El Paso approved settlement terms »

El Paso Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

18:17
09/19/17
09/19
18:17
09/19/17
18:17
Hot Stocks
Bed Bath & Beyond says biggest component in drop of FY17 EPS view is operations »

Company dropped its FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CPRT

Copart

$32.54

-0.32 (-0.97%)

18:11
09/19/17
09/19
18:11
09/19/17
18:11
Earnings
Copart reports Q4 EPS 30c, consensus 29c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STLD

Steel Dynamics

$33.83

0.03 (0.09%)

18:04
09/19/17
09/19
18:04
09/19/17
18:04
Earnings
Steel Dynamics sees Q3 adjusted EPS 63c-67c, consensus 70c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XBKS

Xenith Bankshares

$29.96

0.42 (1.42%)

17:58
09/19/17
09/19
17:58
09/19/17
17:58
Hot Stocks
Treasury exits stake in Xenith Bankshares »

Xenith Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Periodicals
Breaking Periodicals news story on Bristol-Myers »

Times:NHS will supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

BBBY

Bed Bath & Beyond

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

DESP

Despegar.com

17:52
09/19/17
09/19
17:52
09/19/17
17:52
Syndicate
Despegar.com 12.7M share IPO priced at $26.00 »

The IPO priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WAC

Walter Investment

$0.65

0.186 (40.09%)

17:50
09/19/17
09/19
17:50
09/19/17
17:50
Hot Stocks
Walter Investment says Barclays to increase financing available »

On September 13, Walter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

17:49
09/19/17
09/19
17:49
09/19/17
17:49
Initiation
CymaBay initiated at Cantor »

CymaBay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

BBBY

Bed Bath & Beyond

17:46
09/19/17
09/19
17:46
09/19/17
17:46
Hot Stocks
Bed Bath & Beyond sees net drop in Bed Bath & Beyond stores in FY17 »

Says rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

EVH

Evolent Health

$15.65

-0.8 (-4.86%)

17:45
09/19/17
09/19
17:45
09/19/17
17:45
Initiation
Evolent Health initiated at KeyBanc »

Evolent Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

BPL

Buckeye Partners

$56.33

0.64 (1.15%)

17:44
09/19/17
09/19
17:44
09/19/17
17:44
Syndicate
Buckeye Partners announces $210M in limited partnership unit sales »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$91.03

0.87 (0.96%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
Ralph Lauren initiated at Barclays »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

PVH

PVH Corp.

$127.47

-0.54 (-0.42%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
PVH Corp. initiated at Barclays »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

, ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Gemphire…

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

FDX

FedEx

$216.00

0.92 (0.43%)

ADBE

Adobe

$156.60

0.83 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.